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Foxp3 is required for the generation and activity of CD4
 
 
 
CD25
 
 
 
 regulatory T (T reg) cells, 
which are important controllers of autoimmunity, including type-1 diabetes. To determine 
where T reg cells affect the diabetogenic cascade, we crossed the Foxp3 
 
scurfy
 
 mutation, 
which eliminates T reg cells, with the BDC2.5 T cell receptor (TCR) transgenic mouse line. 
In this model, the absence of T reg cells did not augment the initial activation or phenotypic 
characteristics of effector T cells in the draining lymph nodes, nor accelerate the onset of 
T cell infiltration of the pancreatic islets. However, this insulitis was immediately destructive, 
causing a dramatic progression to overt diabetes. Microarray analysis revealed that T reg 
cells in the insulitic lesion adopted a gene expression program different from that in lymph 
nodes, whereas T reg cells in draining or irrelevant lymph nodes appeared very similar. Thus, 
T reg cells primarily impinge on autoimmune diabetes by reining in destructive T cells inside 
the islets, more than during the initial activation in the draining lymph nodes.
 
Type-1 diabetes (T1D) is a prototypical organ-
specific autoimmune disease, caused by T cell
induced autoimmune destruction of the insulin-
producing 
 
 
 
-cells of the islets of Langerhans of
the pancreas. Many of the critical features of
T1D in humans, especially the immunological
aspects, are closely mimicked by the diabetes
that spontaneously arises in nonobese diabetic
(NOD) mice. Autoimmune diabetes in both
humans and mice exhibits two clearly distin-
guishable stages: (a) a clinically occult phase
termed insulitis, featuring infiltration of autoreac-
tive T lymphocytes and other inflammatory
cells into the islets; and (b) an overt diabetes
phase, when extensive destruction of 
 
 
 
-cells
results in a deficiency in insulin production
and ultimately hyperglycemia. The silent insulitic
state, reflected by circulating autoantibodies to
pancreas constituents, can persist for long periods
of time, suggesting that immunoregulatory
controls are able to keep autoreactive T cells
in check.
The asynchrony of the disease in NOD
mice can make it difficult to dissect elements
controlling the initiation and progression of
autoimmune diabetes. To simplify the NOD
model, several groups have developed lines of
TCR transgenic mice with exaggerated reac-
tivity to pancreas autoantigens. One of these is
the BDC2.5 line, which expresses the TCR of
a diabetogenic CD4
 
 
 
, Th1-like, T cell clone
(1, 2). The BDC2.5 TCR recognizes an un-
known antigen presented by the NOD MHC
class II molecule, A
 
g7
 
. In BDC2.5/NOD
mice, the vast majority of T lymphocytes are
reactive against islets. The disease initiation
phase is very synchronous in these animals:
massive insulitis begins sharply between 2 and
3 wk of age in all mice, after an initial activation
of clonotypic T cells in the draining pancreatic
lymph nodes (PLNs) (2–4). On the other hand,
islet destruction and full-blown diabetes appear
highly regulated in BDC2.5/NOD mice, most
animals never progressing to full-blown diabetes.
Furthermore, when the BDC2.5 transgene
was introduced into NOD.
 
Rag
 
o/o
 
 mice, fully
penetrant and rapid diabetes was observed (5),
suggesting the presence of protective lympho-
cytes. Indeed, cells with protective capacity
have been demonstrated in the BDC2.5/NOD
mouse in multiple studies (5–8).
The nature and diversity of T lymphocytes
with regulatory properties remain poorly un-
derstood (9,10), but the best characterized of
these cells are undoubtedly those conditioned
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by the Foxp3 transcription factor. The importance of Foxp3
in regulatory processes was realized when it became clear
that loss-of-function mutations in its gene were responsible
for a severe autoimmune syndrome in humans that com-
monly manifests as lymphadenopathy and multi-organ au-
toimmune damage Similarly, in mice, null mutations of
 
Foxp3
 
 cause massive lymphoproliferation and widespread in-
flammatory infiltration of organs (for review see reference
11). Foxp3 is expressed at the highest level in CD4
 
 
 
CD25
 
 
 
T reg cells, a population recognized as having potent regula-
tory capacity (for review see reference 12). Indeed, recent
results indicate that Foxp3 behaves as a master regulator of
the T reg phenotype (for review see reference 13).
A question currently under intensive investigation is pre-
cisely how Foxp3-dependent T reg cells control the devel-
opment of autoimmune diseases in general and type-1 diabe-
tes in particular. In vitro studies have demonstrated that T
reg cells, which do not themselves actively divide, suppress
the proliferation of effector T (T eff) cells and their produc-
tion of cytokines (9, 12). However, it is now accepted that
their proliferative incapacity is particular to in vitro condi-
tions, as T reg cells proliferated readily in vivo in several ex-
perimental contexts (14, 15). In vivo, the protective role of
T reg cells has been established in a variety of autoimmune
diseases (12), including T1D (6–8, 16–21), but just how this
protection occurs remains unclear. Several mechanisms have
been proposed, e.g., preventing proper localization of T eff
cells in the draining LNs; suppressing their activation, prolif-
eration or differentiation into T eff cell subsets; inducing
anergy in pathogenic T cells; modulating the function of
APCs; inhibiting memory T cell accumulation; and gener-
ally restraining inflammatory pathology (10, 12, 22, 23).
However, most in vivo studies of T reg cells to date have
used experimental systems where they were transferred, to-
gether with effector cells, into lymphopenic hosts. This situ-
ation has greatly complicated the interpretation of the re-
sults: pathology that arose likely entailed enhancement of
self-reactivity in the effector population through the acquisi-
tion of heightened responsiveness associated with homeo-
static expansion (24, 25). Because T reg cells are known to
interfere with homeostatic expansion (26, 27), it was possible
that the regulatory activity was simply a side effect of pre-
venting homeostatic expansion (27).
Knowing the location and mechanism of T reg cell ac-
tion in vivo is essential to understanding its role in immune
regulation, and to potentially harnessing its capacities for
therapeutic purposes. In this study, we bred a null mutation
of the 
 
Foxp3
 
 gene onto the NOD genetic background, and
used the BDC2.5 model to analyze the impact of Foxp3 and
T reg cells on the development of autoimmune diabetes, in
particular as it evolves between disease initiation in the sec-
ondary lymphoid organs and execution in the target tissues. 
 
RESULTS
Fulminant diabetes in Foxp3-deficient BDC2.5/NOD mice 
 
NOD.
 
Foxp3
 
sf
 
 congenic mice that carry a null mutation of the
 
Foxp3
 
 gene, 
 
scurfy
 
 (28), were generated by backcrossing the
mutation (originally from the C57BL/6 genetic background)
onto the NOD/Lt background. Experimental animals came
from the 7–11th generation of backcrossing. All 
 
idd
 
 loci were
verified to be homozygous for the NOD alleles by the sixth
generation. As do Foxp3-deficient mice on other genetic
backgrounds (11), NOD.
 
Foxp3
 
sf
 
 animals developed severe
lymphoproliferation and inflammatory infiltration of multiple
organs, particularly the liver, skin, and lungs. At 2 wk old, the
NOD mutants developed exocrine pancreatitis and occa-
sional peri-insulitis, but invasive insulitis or diabetes was not
detected by 3 wk of age, when they began to die.
 To generate BDC2.5 TCR transgenic mice lacking T
reg cells, we crossed NOD.
 
Foxp3
 
sf
 
 with BDC2.5/NOD ani-
mals. The presence of the BDC2.5 TCR transgene dramati-
cally ameliorated the lymphoproliferation and multi-organ
Figure 1. Very early diabetes onset in Foxp3-deficient BDC2.5/NOD 
mice. (left) Diabetes development in BDC2.5/NOD.Foxp3sf mice (n   20) 
compared with BDC2.5/NOD (n   21) or BDC2.5/NOD.Foxp3sf/  (n   25) 
littermates. (middle) Incidence of diabetes in BDC2.5/NOD.Rago/o mice 
(n   8) compared with that in BDC2.5/NOD.Rag /o controls (n   7). 
(right) Diabetes development in BDC2.5/NOD.Rago/oFoxp3sf and BDC2.5/
NOD.Rago/o littermates (n   6 in each group).  
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infiltration (unpublished data). On the other hand, diabetes
occurred in a dramatic fashion in BDC2.5/NOD.
 
Foxp
 
3
 
sf
 
mice, with onset as early as 16 d of age, and 100% incidence
by 21 d (Fig. 1, left). No diabetes was detected in BDC2.5/
NOD male or BDC2.5/NOD.
 
Foxp
 
3
 
sf/
 
 
 
 female littermates. 
We then compared diabetes development in BDC2.5/
NOD.
 
Rag
 
o/o
 
 mice, which is another model of aggressive dia-
betes that is attributed to a lack of regulatory T cells. Indeed,
these mutants had few cells with a regulatory CD25
 
 
 
CD69
 
 
 
phenotype (unpublished data). Diabetes developed rapidly in
BDC2.5/NOD.
 
Rag
 
o/o
 
 mice, but was slower than in their
Foxp3-deficient counterparts (Fig. 1, middle; 18 
 
 
 
 1 vs. 25 
 
 
 
3 mean age of onset, P 
 
  
 
6 
 
 
 
 10
 
 
 
11
 
). 
To test whether Foxp3 has a function in pathogenic ef-
fector T cells, we crossed the Foxp3-null mutation into the
BDC2.5/NOD.
 
Rag
 
o/o
 
 line. Diabetes developed with iden-
tical kinetics in the BDC2.5/NOD.
 
Rag
 
o/o
 
 and BDC2.5/
NOD.
 
Rag
 
o/o
 
Foxp3
 
sf
 
 groups (Fig. 1, right), indicating that
Foxp3 affects only the T reg compartment in this system,
and plays no required role in pathogenic effector cells. The
subtle delayed diabetes in BDC2.5/NOD.
 
Rag
 
o/o
 
 and BDC2.5/
NOD.
 
Rag
 
o/o
 
Foxp3
 
sf
 
 mice is most likely caused by the slightly
later onset of insulitis in the RAG-deficient context (refer-
ence 5; unpublished data). 
 
A deficit in CD25
 
 
 
 T reg cells in Foxp3-deficient 
BDC2.5 mice
 
At this stage, it was important to validate the experimental
model by confirming that, as anticipated (29), the Foxp3
deficiency led to a dearth of T reg cells in BDC2.5/
NOD.
 
Foxp3
 
sf
 
 animals. Flow cytometric analyses demon-
strated that the differentiation, lineage commitment, and ac-
cumulation of clonotype-positive thymocytes were normal,
as was their export to the secondary lymphoid organs (un-
published data). On the other hand, BDC2.5/NOD.
 
Foxp3
 
sf
 
mice exhibited a deficit in CD25
 
hi
 
 cells of the T reg pheno-
type (Fig. 2 a); those CD25
 
 
 
 T cells that remained, displayed
the lower level of CD25 typical of activated cells. The deficit
was manifest in both the spleen and the PLN.
If the accelerated diabetes of BDC2.5/NOD.
 
Foxp3
 
sf
 
 mice
results from the absence of CD25
 
 
 
 T reg cells, it should be in-
hibitable by complementation with this population. Thus,
we reconstituted neonatal BDC2.5/NOD.
 
Foxp3
 
sf
 
 mice with
freshly isolated T reg cells from BDC2.5/NOD mice. Injec-
tion of 7 
 
 
 
 10
 
5
 
 CD4
 
 
 
CD25
 
 
 
 cells from BDC2.5/NOD mice
protected all BDC2.5/NOD.
 
Foxp3
 
sf
 
 recipients from early on-
set diabetes (Fig. 2 b); however, this protection waned with
time, the mice becoming progressively diabetic between 40
and 120 d. The duration of the protection was dose depen-
dent, as the transfer of lower numbers of CD4
 
 
 
CD25
 
 
 
 cells
resulting in earlier escape from protection (Fig. 2 b). Previous
studies have reported that T reg cells derived from BDC2.5
mice, with their enriched antiislet repertoire, are far more ef-
fective in protecting from diabetes than those from standard
NOD mice (6, 7). This enhanced effectiveness was also ob-
served in this neonatal transfer system, as no protection was
conferred by equivalent numbers of CD4
 
 
 
CD25
 
 
 
 cells from
nontransgenic NOD donors (Fig. 2 c). 
Figure 2. A deficit in T reg cells in Foxp3-deficient BDC2.5/NOD 
mice caused accelerated diabetes. (a) The T reg deficiency in BDC2.5/
NOD.Foxp3sf mice. CD4 CD25  T cells from 12-d-old BDC2.5/NOD.Foxp3sf 
and BDC2.5/NOD littermates were enumerated by flow cytometry. Plots 
were gated on lymphoid, CD4 CD8 CD69 B220 CD11b 7AAD  cells. Each 
group consisted of four to five mice from two to three independent experi-
ments. The number within the plot refers to the mean percentage ( SD) of 
cells in the counting gate. (b) Treatment with antigen-specific T reg cells 
from BDC2.5/NOD mice rescued BDC/NOD.Foxp3sf mice from early diabetes. 
(c) Nonspecific T reg cells from NOD mice were not effective in suppressing 
diabetes in BDC2.5/NOD.Foxp3sf mice. The CD25  group represents a com-
posite of five BDC2.5/NOD.Foxp3sf mice injected with 7   105 BDC2.5 cells 
and three mice with 105 cells. Each of the CD25  groups consists of four to 
six animals. The BDC2.5/NOD.Foxp3sf/  group consists of 15 mice. 
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No impact of T reg cells on T cell activation in the PLN
 
The different kinetics of diabetes development displayed by
BDC2.5/NOD versus BDC2.5/NOD.
 
Foxp3
 
sf
 
 mice reflect
solely the absence of T reg cells in the latter, providing a clean
model to test where the regulatory population impinges on
pathogenesis. In particular, perturbation induced by transfer of
cells into lymphopenic hosts is not at play. Here, we analyzed
the unfolding of diabetes in BDC2.5/NOD.
 
Foxp3
 
sf
 
 mice, fo-
cusing on the checkpoints known to demarcate the initiation
and progression of disease in the BDC2.5 model.
A possible explanation for the more aggressive diabetes of
BDC2.5/NOD.
 
Foxp3
 
sf
 
 mice is that T reg cells blocked the
initial encounter of antigen by pathogenic T cells in the PLN,
a very possible scenario since it has been proposed that T reg
cells perturb DC maturation and antigen presentation (18), or
block localized interaction between APCs and T eff cells in
the PLN (22). We tested this possibility by evaluating the ex-
pression of the CD69 and CD44 activation markers in the
PLN of BDC2.5/NOD.
 
Foxp3
 
sf
 
 mice or Foxp3-positive con-
trol littermates. At day 12, only a minimal number of CD4
 
 
 
 T
cells expressed CD69 in either type of mice (Fig. 3, a and
b). By day 15, 5–30% of CD4
 
 
 
 T cells in the PLN be-
came CD69 , but there was no notable difference between
BDC2.5/NOD.Foxp3sf mice and BDC2.5/NOD controls
(Fig. 3 b). Also, no difference was found when gating the anal-
ysis on those CD4  cells staining at high levels with a mono-
clonal antibody specific for the BDC2.5 clonotype (Fig. 3 c), a
population that was demonstrated to be diabetogenic (30). 
One of the hallmarks of T reg cells is their ability to non-
specifically suppress the proliferation of T cells stimulated
through their TCRs, at least in vitro (9, 12). Thus, it was con-
ceivable that T reg cells limit the activation of BDC2.5/NOD
T cells, and that the release of this damper by the elimination
of T reg cells in BDC2.5/NOD.Foxp3sf mice led to runaway
proliferation. In vivo proliferation of BDC2.5 effectors in the
PLN of BDC2.5/NOD and BDC2.5/NOD.Foxp3sf mice was
compared by quantitating the incorporation of 5-bromo-2-
deoxyuridine (BrdU). Mice were injected with BrdU at 15 d
old, and BDC2.5-clonotypehi T cells from the PLN were ana-
lyzed for incorporation of BrdU after a 6-h labeling period. As
shown in Fig. 4 (a and b), the clonotypehi effectors proliferated
to an equivalent extent in BDC2.5/NOD and BDC2.5/
NOD.Foxp3sf littermates. This observation was consistent
with the absolute number of BDC2.5 clonotypehi cells, which
was equivalent in the PLN of the two types of mice (for
BDC2.5/NOD, 4.1   0.9   104,  n     8; for BDC2.5/
NOD.Foxp3sf, 3.6   1.8   104, n   5). In contrast, although
we could recover 2,000–5,000 T cells from the pancreas of a
15-d-old BDC2.5/NOD.Foxp3sf mouse, we could isolate
only 50–100 T cells from a BDC2.5/NOD control. 
Although the activation and proliferation of autoreactive
T cells did not seem to be affected by the presence of T reg
cells in the PLN, it is possible to hypothesize that their dif-
ferentiation status and cytokine profile might be altered—for
example, inhibiting the differentiation along a pathogenic
Th1 pathway. Flow cytometric and quantitative RT-PCR
were performed on clonotypehiCD25 /lo cells from the PLN
of BDC2.5/NOD.Foxp3sf mice and control littermates. No
difference was seen in the levels of mRNAs encoding IL-2
or IFN  (Fig. 4, c and d). No IL-4 mRNA was detected in
either group (unpublished data). There was no difference
in the expression of costimulatory molecules: CD134 was
found in low and variable numbers of clonotypehi cells; there
was some variability between mice, which is understandable
because the very first stages of insulitis were examined, but
with no notable difference between mutant and control
mice (Fig. 4 e); no expression of ICOS was detected in ei-
ther group. A previous study suggested that T reg cells in-
hibit chemokine receptor CXCR3 by T eff cells in the PLN
and thus control the trafficking of these cells to the pancreas
(19). We could not detect substantial CXCR3 expression on
T cells from the PLN of the 15-d-old mice with or without
T reg cells (unpublished data). The expression of another
chemokine receptor, CCR5, also implicated in diabetes
progression (31), was not substantially different between
BDC2.5/NOD and BDC2.5/NOD.Foxp3sf mice (Fig. 4 f). 
Figure 3. Naturally occurring T reg cells did not suppress initial 
T cell activation. Similar kinetics of T cell activation in the PLN of BDC2.5/
NOD and BDC2.5/NOD.Foxp3sf littermates, as indicated by the percentage 
of cells expressing CD44 and CD69 activation markers. Gated on either 
CD4  (a and b) or BDC2.5 clonotypehi T cells (c). Cells from the nondraining 
MLNs were used as negative controls; b and c derive from independent 
experiments. Each dot represents one animal. JEM VOL. 202, November 21, 2005 1391
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Also, no impact of T reg cells on the PLN activation and 
proliferation of T eff cells in a transfer system 
Our analysis of BDC2.5/NOD.Foxp3sf mice indicated that
T reg cells did not have a substantial negative influence on
the activation of autoreactive T cells in the draining PLN,
rather seeming to exert their effects within the pancreatic le-
sion, in apparent contradiction with some previous papers
(18, 22, 32). This discrepancy might be linked to the use of
transfer systems in previous analyses, whereas we relied on a
genetic mutation to generate otherwise identical mice with
or without T reg cells. Therefore, we examined the impact
of T reg cells in settings of adoptive transfer. First, we ana-
lyzed activation of the effector T cells in 15-d-old BDC2.5/
NOD.Foxp3sf mice that had received CD25  T reg cells as
neonates (i.e., under conditions in which they are protected
Figure 4. T reg cells did not suppress T cell proliferation, Th1–
cytokine production, costimulatory molecule, and chemokine 
receptor expression in the PLN. (a) Representative plots for BrdU incor-
poration analysis. Each group consists of five to eight mice. The PLN from 
mice that did not receive BrdU (right) served as a negative control. The 
numbers in the plots are percentages of the gated population. Plots are 
derived from BDC2.5 clonotypehiCD8 B220 CD11b  population. (b) Per-
centages (mean   SD) of BrdU-labeled cells in the CD69  and CD69  
subsets shown in panel a. (c and d) PCR Quantification of IL2 (c) and IFN  
(d) mRNA in BDC2.5 clonotypehiCD25  from the PLN of 15-d-old BDC2.5/
NOD versus BDC2.5/NOD.Foxp3sf mice. Data are from two experiments 
with five mice in each group. (e and f) Frequencies of BDC2.5 clonotypehi 
cells expressing the costimulatory molecule CD134 (OX40) and chemokine 
receptor CD195 (CCR5), respectively, in the PLN of 15-d-old BDC2.5/NOD 
versus BDC2.5/NOD.Foxp3sf mice. The dashed line indicates background 
staining. Each dot represents one animal. 
Figure 5.  Transferred T reg cells did not inhibit the activation and 
proliferation of effector T cells in the PLN. (a) CD4 CD25  or CD4 CD25  
cells isolated from Thy1.1 congenic BDC2.5/NOD mice were transferred to 
3-d-old BDC2.5/NOD.Foxp3sf mice, and the activation of endogenous Thy1.2  
T cells in the PLN was analyzed at day 15. The numbers indicate the percentage 
of cells in the respective counting gate. Plots are gated on lymphoid, 
B220 CD8  cells. Data represent three experiments with four to five mice in 
each group receiving 105 or 2.5   105 cells. (b) CD25  T cells from Thy1.1-
congenic BDC2.5/NOD mice were labeled with CFSE, and were injected alone, 
or were mixed with CD4 CD25  or CD4 CD25  cells from BDC2.5/NOD mice 
at a 10:1 or 3:1 ratio, into standard NOD mice. Dilution of CFSE in the trans-
ferred Thy1.1  effectors in the PLN or inguinal LN was analyzed from 52 to 
70 h after injection. The numbers within the plots indicate the percentages of 
cells that exhibit CFSE dilution. Data are from three experiments. T REG CELLS CONTROL AUTOIMMUNE DIABETES IN ISLETS | Chen et al. 1392
from diabetes), as shown in Fig. 2. Donor cells came from
Thy1.1 congenic BDC2.5/NOD mice in order to distin-
guish them from the host, and amounted to roughly 30% of
the T reg frequency in BDC2.5/NOD mice. Accumulation
of transferred T reg cells in the PLN was no more than that
in the nondraining mesenteric LNs (MLNs; Fig. 5 a). The
transferred T reg cells maintained CD25 expression (not de-
picted). As illustrated in Fig. 5 a, the BDC2.5 T reg cells, al-
though they were sufficient to inhibit diabetes, did not sup-
press the PLN-specific induction of CD69 on host T cells.
Second, as one might argue that the large number of
clonotype-positive cells in the host might outnumber the
transferred regulatory cells, we tested the effect of T reg cells
on the activation of cotransferred BDC2.5/NOD effector T
cells. A low number of naive BDC2.5/NOD effector T cells,
labeled with carboxyfluorescein succinimide ester (CFSE),
were transferred alone or mixed with CD4 CD25  T reg or
CD4 CD25  control cells, into 5-wk-old NOD mice; the
proliferation of transferred effector cells was assessed by mea-
suring CFSE dilution. As shown in Fig. 5 b, autoreactive T
cells proliferated vigorously in the PLN but not in irrelevant
inguinal LNs. In the three experiments presented in Fig. 5 b,
no impact of T reg cells on cotransferred T eff cells could be
distinguished, regardless of the ratio or readout time. This re-
mained true even at 200 h after transfer (unpublished data). 
T reg cells’ effect on the progression, but not the timing, 
of insulitis
A potential explanation for the accelerated diabetes in
BDC2.5/NOD.Foxp3sf mice was that the T reg cell defi-
ciency accelerated disease initiation, allowing T cells to infil-
trate the islets at an earlier time. Insulitis begins very sharply
in BDC2.5/NOD mice,  2 wk of age, probably in response
to perturbation in islet physiology (2–4). As shown in Fig. 6,
the time course of insulitis was similar in BDC2.5/NOD
and BDC2.5/NOD.Foxp3sf animals: no islet infiltration was
detected in 12-d-old mice; but, at day 15, islets showed clear
infiltration. The insulitis of BDC2.5/NOD.Foxp3sf mice dif-
fered in that it was immediately aggressive (Fig. 6 a, bottom
right), compared with the “respectful” disposition of invad-
ing cells in animals with T reg cells (Fig. 6 a, bottom left).
Microarray analysis of T reg cell activity in the PLN 
and pancreas
Hence, all lines of evidence indicate that Foxp3-dependent T
reg cells dampen the progression of autoimmune diabetes by
controlling the aggressiveness of autoreactive T eff cells in the
target organ, but have no detectable impact on initial priming
and activation in the draining LNs. To test the robustness of
this conclusion, we sought an independent approach. We
have previously shown that a substantial number of T reg
cells are found in the insulitic lesion of BDC2.5/NOD mice,
identified by their CD25 CD69  phenotype and by their
strong expression of Foxp3 (8). If the target organ is the loca-
tion where T reg cells show their main action, it is reasonable
to expect that an alteration in their gene expression profiles
might subtend this functional role. Therefore, we performed
a comparative microarray analysis of three different tissues
from 3- to 4-wk-old BDC2.5/NOD mice: the MLN, an ir-
relevant LN devoid of antigenic stimulus for BDC2.5 T cells;
the draining PLN, where priming and activation of BDC2.5
cells occurs; and the pancreas, where infiltrate cells are in di-
rect contact with the antigen source. For all three locations,
we isolated both the CD4 CD25 CD69  T reg cell popula-
tion ( 80–90% stain positive for intracellular Foxp3 protein
and there is no difference among the cells isolated from the
three locations) and the remainder of the CD4  cells (only
2–5% are Foxp3 ; Fig. 7 a). The six populations should de-
fine profiles that distinguish, for all three organs, T reg cells
from their conventional counterparts. Total RNA was pre-
pared from purified cells, amplified, and used to generate probes
for Affymetrix Mu74Av2 chips. Data were preprocessed with
the RMA algorithm, and averaged between at least three in-
dependent replicates for each condition. False discovery rates
were estimated by generating randomized datasets based on
the intra-replicate distribution of variance.
Figure 6. Naturally occurring T reg cells regulated the aggressive-
ness of insulitis. (a) Precipitous progression of Insulitis in Foxp3-deficient 
BDC2.5/NOD mice. Pancreatic sections stained with hematoxylin and eosin 
(original magnification, 200), representative of four to five mice in each 
group. (b) Scores of insulitis at 12 and 15 d old. Each bar represents 
one animal. JEM VOL. 202, November 21, 2005 1393
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We initially sought to define a general “T reg signature,”
a set of genes whose over- or underexpression distinguishes
the CD4 CD25  population from conventional CD4  T
cells (hereafter Tconv) in different contexts. For a robust
definition of this signature, we used the present datasets to-
gether with T reg expression profiles from two other inde-
pendent sources. Fontenot et al. have performed a microar-
ray analysis of T reg cells identified by a fluorescent protein
reporter “knocked-in” the Foxp3 locus (33); these data were
obtained with lymph node T reg cells from unchallenged
mice (hereafter referred to as the Seattle data). Huehn et al.
(34) have analyzed different phenotypic variants of T reg
cells, in particular those marked by the expression of CD103
( E 7 integrin), which reside preferentially in inflamed tis-
sues (hereafter referred to as the Berlin data). These addi-
tional datasets allowed us to perform a combined selection
procedure, diagramed in Fig. 7 b, where validation is pro-
vided by discovery in independent datasets. The Seattle
datasets provide a perspective on “central” T reg cells resid-
ing in lymphoid organs, whereas the Berlin datasets highlight
genes particularly expressed in “peripheral” T reg cells in
the tissues. In practice, we first identified all genes in the
BDC2.5/NOD datasets that were overexpressed in T reg
relative to Tconv cells by 1.4-fold in any one of the three
comparisons: MLN, PLN, or pancreatic infiltrate (this initial
fold-change cutoff, which corresponds to a false-discovery
rate of 0.18 for single datasets, or 0.25 in any one of the
three, was voluntarily chosen as being nonstringent). This
primary set of 556 genes was then cross-matched with the
other two T reg/Tconv comparisons. 212 genes were found
to be overexpressed also by T reg cells in either the Berlin or
Seattle data groups. The same operation was performed for
genes underexpressed in T reg cells: 831 primary calls, of
which 96 were shared with either the Berlin or Seattle data.
These cross-comparisons resulted in highly notable assign-
ments, because the same process run on randomized datasets
resulted in only 22 and 4 genes apparently over- or under-
expressed in the T reg population. In addition, 15 genes
were internally reproduced, as different features on the chip
yielded identical results. (Table S1, available at http://
www.jem.org/cgi/content/full/jem.20051409/DC1).
We then asked how the genes in the T reg signature com-
pared with BDC2.5/NOD T reg cells from the MLN, PLN,
and pancreatic infiltrate. As illustrated by the expression values
plotted in Fig. 7 c, the profiles of the two LN T reg popula-
tions were much more similar to each other than they were to
the profile of infiltrating T reg cells (altogether 30 vs. 5 genes
varying by twofold or more, the latter being equivalent to
normalized background). This finding was confirmed in the
displays of Fig. 8, which plots “T regness” on the x axis (the
max ratio of expression between T reg and T conv, calculated
within each tissue pair) versus the expression ratio between T
reg populations on the y axis. Several points can be made
from this means of displaying the data. First, many of the T
reg signature genes were distinctly over- or underexpressed in
islet-infiltrating T reg cells relative to T reg cells in the control
MLN (Fig. 8 a, right). In contrast, there was much less differ-
ence between the PLN and MLN T reg cells (Fig. 8 a, left).
These differentially expressed genes included IL-10, an im-
portant mediator of T reg cell activity, CD103, and S100a6,
which have previously been described as characteristic of
effector/memory T reg cells (34); and chemokine receptors
that would account for their different location (up-regulated,
Ccr5, Cxcr3, and Ccr2; down-regulated, Ccr6). Second, this
differential expression primarily concerned the overexpressed
genes of the T reg signature (Fig. 8 b, top); genes under-
expressed in T reg cells were more stable overall (Fig. 8 b,
bottom). Third, the genes whose expression diverged most in
the infiltrating T reg cells tended to be those with the highest
T reg/T conv differential. Thus, the T reg cells present in the
pancreatic infiltrate, at the location where they are effectively
suppressing tissue damage, have a phenotype quite distinct
from that of their counterparts residing in the lymph nodes,
and one that seems to amplify T reg characteristics.
DISCUSSION
Among the shared characteristics of T1D in humans and mice
is the slow progression of the disease in most cases. In humans,
serum autoantibodies against islet antigens, indicators of islet
Figure 7.  Gene expression profiles of T reg cells in the respectful 
insulitic lesion and in lymph nodes. (a) Sorting gates for the CD4 CD25  
or CD4 CD25  cells isolated from MLNs or PLNs, or from the pancreatic 
infiltrate. (b) Definition of the T reg signature. Genes were identified by 
comparing microarray datasets from the pairwise comparison of popula-
tions shown in panel a (left boxes) or from published datasets: lymph node 
GFP CD25  T reg cells versus naive GFP-CD25  cells from the Foxp3gfp 
knockin mice (33), or CD103 CD25  versus CD103 CD25  cells from B6 
mice (reference 34). Genes detected as differentially expressed in two of 
the three datasets were included in the signature gene set. (c) Biparameter 
plots comparing expression values of genes from the T reg signature in 
T reg cells of the MLNs, PLNs, or pancreatic infiltrate. The number of genes 
over- or underexpressed in either condition is shown in the plot.T REG CELLS CONTROL AUTOIMMUNE DIABETES IN ISLETS | Chen et al. 1394
inflammation, can appear years before overt diabetes. In NOD
mice, insulitis begins at  3–4 wk after birth, but diabetes does
not manifest until 12 wk of age. Studies with the BDC2.5
model have highlighted two checkpoints in disease progres-
sion, as well as a critical role for Foxp3-dependent CD25  T
reg cells (6–8). Here, we asked where and how T reg cells ex-
ert their control on the unfolding of diabetes, under experi-
mental conditions not influenced by homeostatic expansion of
the effector population. Several lines of evidence converged to
demonstrate that T reg cells do not delay or hinder the activa-
tion and expansion of antiislet T cells in the PLN, nor the
timing of their infiltration of the islets. Although we detected
no change in initial activation, proliferation, cytokine produc-
tion, chemokine receptor, and costimulatory molecule ex-
pression of T eff cells in the PLN, we cannot formally exclude
a subtle effect on T eff cells in the LN that would precede and
predict their mode of response once they home to the islet.
Yet the most obvious impact is in the target tissue, arguing
that this is the location where T reg cells primarily act, to con-
trol an otherwise destructive infiltration. In keeping with this
tissue-localized activity, we found a clear shift in the gene ex-
pression profiles of islet-resident T reg cells from the T reg
signature characteristic of lymphoid-tissue cells.
The scurfy model offers complete but isolated ablation of
Foxp3-dependent T reg cells, which is different from the situa-
tion with other genetically engineered or transfer systems that
induce variations in their number or activity, or where the mu-
tation may have other consequences. For example, the numbers
of CD25  T reg cells in CD28 /  or B7 /  mice are greatly
reduced, but substantial populations still exist (16) and antigen
presentation is also affected. Adoptive transfer models often take
the absence of CD25 to denote effector cells, but CD25  T
regs can emerge from CD25  populations after transfer (35). 
As suggested by Tarbell et al. (7), the physiological func-
tion of CD25  T reg cells needs to be addressed under con-
ditions independent of lymphopenia-induced homeostasis,
and BDC2.5/NOD.Foxp3sf animals meet this condition. We
compared the initial antiislet T cell activation in the PLN
with or without T reg cells, under conditions where both T
eff and T reg cells have matured in vivo without perturba-
tion. In BDC2.5/NOD mice, and most likely in standard
NOD mice as well (36), activation of BDC2.5 T cells in the
PLN is under tight temporal control. Before 12 d old, there is
no notable T cell activation (3), and we have suggested that
overcoming this “checkpoint 1” is linked to a ripple of devel-
opmentally regulated  -cell apoptosis (4). Although it is rea-
sonable to propose the counterinterpretation that T reg cells
are involved in this delay, in keeping with suggestions that
they can keep DCs from maturing until released by a CD40-
dependent T cell help signal (18), our data refute this scenario
because the absence of T reg cells did not accelerate the tim-
ing of the initial antiislet T cell activation and insulitis.
Figure 8.  Nature of the genes that distinguish T reg cells in the 
pancreatic infiltrate. (a) The biparameter plots show, for all genes of the 
T reg signature, the ratio of expression values in T reg or T conv cells (T reg/
T conv, x-axis) versus the ratio of expression in pancreatic infiltrate T reg 
cells versus MLN T reg cells (right); as a control, the ratio between T reg 
cells in PLN and MLN is shown on the left. (b) Nature of the genes whose 
expression is altered in T reg cells of the pancreatic infiltrate relative to 
LNs T reg cells. The first three columns give the ratio of expression in T reg 
cells versus conventional CD4  cells of the MLN or pancreas (Tr/Tc MLN 
and Tr/Tc Panc, respectively), and the ratio of pancreatic versus MLN T reg 
cells (Tr Pa/LN). The NCBI gene symbol is used, along with the NCBI GeneID 
identifier. Yellow and orange highlights denote genes overexpressed
by  1.35- or 2.5-fold, respectively; blue highlight denotes underexpres-
sion by  0.6 fold.JEM VOL. 202, November 21, 2005 1395
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The absence of an impact of T reg cells on the initial anti-
islet T cell activation phases in the draining PLN contrasts
with previous findings in other models of autoimmune diabe-
tes, where it has been suggested that T reg cells suppressed the
homing of effector T cells to the PLN or activation or prolif-
eration therein. On the basis of results from experiments per-
formed with in vitro expanded islet-specific T reg cells, it was
suggested that BDC2.5 T reg cells intervene in the PLN by
excluding localized interaction between BDC2.5 effector T
cells and APCs (22). However, this result may have reflected
the pharmacological effect of in vitro activation and expansion
of the T reg cells and/or numeric effects beyond their physio-
logical role. In the same vein, another paper proposed that T
reg cells controlled the pathogenic effect of an islet-specific,
CD8  TCR transgene–encoded T cell specificity by inhibit-
ing DC maturation in the PLN (18), but this study did not di-
rectly demonstrate the impact of transferred T reg cells on the
activation of the CD8  effector cells in the PLN. In another
study (32), thymectomized NOD.B7-2o/o recipients were
treated with anti-CD25 antibodies to deplete T reg cells, and
the division of CFSE-labeled naive BDC2.5 T cells transferred
into these recipients was measured 2 wk later in the PLN.
Compared with control animals, the PLN of anti-CD25-
treated mice harbored about twofold more BDC2.5 T cells
that had undergone division, suggesting that the T reg cells
suppress the activation of autoreactive T cells in the draining
lymph nodes (32). However, this impact was modest and anti-
CD25 treatment is not without other effects.
On the other hand, results from several systems are com-
patible with a role for T reg cells in preventing the locally
damaging consequences of autoimmune infiltration. In a
transgenic model where diabetes was provoked by islet-spe-
cific expression of TNF  and CD80, the transfer of T reg cells
protected the recipients from diabetes and invasive but nonde-
structive insulitis was detected in the pancreata of the pro-
tected mice (17). In one of our previous studies, sorted
CD4 CD25 /lo effector cells from pancreata of BDC2.5/
NOD mice transferred diabetes into NOD.scid recipients. The
diabetes was inhibited by cotransfer of CD25  T reg cells that
were also isolated from pancreata of BDC2.5/NOD mice; in-
sulitis was clearly present in the protected mice, and had ac-
quired the respectful aspect characteristic of the stably bal-
anced lesions of BDC2.5/NOD mice (8). In another study,
diabetes occurred a few weeks after transfer of splenocytes
from diabetic NOD mice into NOD.scid recipients, but dis-
ease was suppressed for months by cotransfer of BDC2.5/
NOD CD25  T reg cells expanded in vitro with DCs plus a
mimotope peptide (7). Histological examination revealed that
insulitis was clearly present, but appeared controlled, in the
protected mice (7), again pointing to local control. The de-
layed onset of insulitis may have been caused by an effect of T
reg cells in suppressing lymphopenia-induced homeostatic ex-
pansion. Recently, Sarween et al. (19) have reported the ac-
tion of T reg cells in a model where diabetes was induced in
RAG-deficient mice carrying the RIP-mOVA transgene and
transferred with ovalbumin-specific transgenic T cells. As
here, T reg cells had little or no impact on the activation of ef-
fector cells. The results differed, however, in that T reg cells
appeared to have an effect on IFN  production by T eff cells
in the PLN, which was not the case here. In addition, T reg
cells seemed to slow the migration of OVA-specific cells into
the islets, perhaps through a reduction in CXCR3 in the
PLN. Again, this was not the case here, as insulitis appeared
with the same kinetics in the presence and absence of T reg
cells. The difference might be explained by the different anti-
gens involved (natural pancreatic autoantigen vs. transgenic
foreign antigen), and the latter also requiring an additional im-
munization in adjuvant to break a state of “clonal ignorance.” 
That T reg cells predominantly affect effector cells in a de-
layed manner and in the target tissues has also been suggested
in other contexts. Huehn et al. showed that regulatory T cells
with a memory phenotype akin to those of tissular lympho-
cytes were more effective suppressors of arthritis in vivo than
were their naive counterparts (34). With hemagglutinin as a
foreign antigen, T reg cells had no impact on the early phase
of the response, but prevented the later accumulation of effec-
tor cells (15). T reg cells have also been detected, and shown
to be active, in local infiltrates marking ear infection by Leish-
mania major (37) or in tolerated cardiac allografts (38). They
were also present in lymphoid populations infiltrating tumors,
where they were thought to hamper the efficacy of tumor-
specific effectors (39). Consistent with the present findings, T
reg cells did not inhibit proliferation and IFN  production by
T eff cells in the draining LNs, in a mouse model of tumor re-
jection by transferred antigen-specific CD8  T cells (40). Fi-
nally, CD25  T reg cells could inhibit local inflammation
even when there were no T cells involved (and per force no
activation in the draining lymph node), such as in the Helico-
bacter-dependent colitis model in Rag2 /  mice (41). 
Consistent with the predominant role of T reg cells in the
insulitic lesion, we found that they acquired a distinct gene
expression profile, relative to T reg cells residing in the LNs.
Some of the changes were consistent with their tissular local-
ization, and overlapped to a large extent the transcriptional
differences between circulating and tissue-homing T reg cells
observed by Huenh et al. (34). Others were more evocative
of physiological changes linked to their antiinflammatory
function, most notably a strong increase in IL-10 transcripts.
Although these observations are correlative, they are quite
consistent with a view where the tissular action of T regs is
accompanied by an amplification of their specific phenotype. 
In conclusion, the dramatic diabetes of BDC2.5/NOD.
Foxp3sf mice illustrates the requirement for Foxp3-dependent
CD25  T reg cells in maintaining a balanced insulitis. This ef-
fect illustrates the great therapeutic potential of T reg cells, and
also argues that it will be highly desirable to target their action
to the tissue where they may be most effective.
MATERIALS AND METHODS 
Mice. B6.Cg-Foxp3sf mice on the C57BL/6 background, provided by F.
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NOD/Lt background. The Foxp3sf mutation was identified by PCR (primers:
5 -TCAGGCCTCAATGGACAAGA-3  and 5 -GCCCAAGGCTATG-
CATTTAT-3  for WT Foxp3; 5 -TCAGGCCTCAATGGACAAAA and
GCCCAAGGCTATGCATTTAT-3  for Foxp3sf mutant). Breeders in the
backcross were also genotyped for microsatellite markers linked to diabetes
susceptibility/resistance loci Idd1 through Idd20. The loci that have a major
impact on diabetes incidence were fixed to NOD alleles early in the back-
crossing. By the sixth generation of backcrossing (N6), all Idd loci were ho-
mozygous for the NOD alleles. The Foxp3 gene is located on the X chromo-
some at the 2.1 cM position. Although there is no Idd locus on the X
chromosome, we minimized the contamination of non-NOD genes from the
X chromosome. A large number of offspring from the N6 generation were
screened for recombination on the X chromosome by typing microsatellite
markers near the Foxp3 gene. One female carrier of Foxp3sf mutation was
found to be homozygous for the NOD alleles at both DXMit136 (located at
2.8cM) and DXMit166 (located at 15.5cM). This founder was selected for
further backcrossing. Experimental mice are from the 7–11th generations.
NOD.Foxp3sf mice were crossed with BDC2.5/NOD to generate BDC2.5
mice deficient in Foxp3. This line was also crossed with NOD.Rag1o/o (The
Jackson Laboratory) and F1 offspring were intercrossed to generate
NOD.Rago/oFoxp3sf/  mice. NOD.Rago/oFoxp3sf/  mice were further crossed
with BDC2.5/NOD.Rago/o mice protected from early diabetes by normal
NOD splenocytes (5), to generate BDC2.5/NOD.Rago/oFoxp3sf mice on the
NOD background. NOD.Thy1.1 mice (The Jackson Laboratory) were
crossed with BDC2.5/NOD; backcrossing F1 offspring with NOD.Thy1.1
generated BDC2.5/NOD.Thy1.1 mice. Mice were maintained in the Joslin
Diabetes Center barrier facility (protocol 99–19, 99–20 approved by the Joslin
Diabetes Center’s International Animal Care and Use Committee).
Diabetes monitoring and insulitis scoring. Urine glucose levels were
tested every 2– 3 d with Uristix (Bayer Diagnostics). Positive reads were
confirmed by blood glucose measuring ( 250 mg/dl) with a Glucometer 3
reader (Bayer Diagnostics). To score insulitis, pancreata were fixed in forma-
lin solution (Sigma-Aldrich). Paraffin-embedded sections were stained with
hematoxylin and eosin and examined by microscopy. Multiple hematoxylin
and eosin sections of pancreata and at least 40 islets per animal were assessed.
Peri-insulitis refers to the presence of inflammatory cells in the immediate vi-
cinity of the islets and insulitis includes all invasive infiltration in the islets. 
Flow cytometry. Single cell suspensions of lymphoid organs or blood
leukocytes were prepared and blocked with anti-CD16/32 (2.4G2) and
normal mouse sera (Jackson ImmunoResearch) against Fc-mediated non-
specific binding of antibodies. The samples were then stained with antibody
conjugates with a standard procedure. The following antibody conjugates
were used: biotinylated anti-BDC2.5 TCR; FITC conjugated anti-CD44,
anti-TCR , anti-Thy1.1, anti-CD25 (BD Biosciences); PE conjugated
anti-CD62L, anti-CD69, anti-CD25, anti-Thy1.2, anti-ICOS (BD Bio-
sciences), anti-CD134 (OX40) (eBioscience), and streptavidin (Biosource
International); PE-Cy5 conjugated anti-CD8, anti-CD69, anti-CD11b
(Caltag), anti-B220 (BD Biosciences) and anti-Thy1.2 (eBioscience); PE-
Texas Red conjugated anti-CD4, anti-CD8 and anti-B220 (Caltag). Cell-
surface expression of CXCR3 and CCR5 and intracellular expression of
Foxp3 were examined with PE-conjugated monoclonal antibodies (R&D
Systems, BD Biosciences, and eBioscience, respectively) according to the
manufacturers’ protocols. Staining with 7-aminoactinomycin D (7-AAD;
Sigma-Aldrich) was used to exclude dead cells. Stained samples were ana-
lyzed with a flow cytometer (EPICS XL; Beckman Coulter).
 For assessment of T cell proliferation by incorporation of BrdU, 0.5
mg BrdU was injected intraperitoneally into 15-d-old mice. 6 h later, ani-
mals were killed and cells from the PLN were stained for BDC2.5 clono-
type and CD69, and then for incorporated BrdU with anti-BrdU antibody
(BD Biosciences) following the manufacturer’s protocols. 
Cell sorting and adoptive transfer. Splenocytes of NOD or BDC2.5/
NOD mice were blocked against Fc-binding as stated above, stained with
anti-CD4-APC, CD-25-PE, CD8-FITC, B220-FITC, CD11b-FITC,
CD69-FITC (BD Biosciences) and sorted with a MoFlo cytometer and Sum-
mit software (DakoCytomation) for CD8 B220 CD11b CD69 CD4  cells
that are either CD25  or CD25  (purity  95%). Sorted cells were re-
suspended in PBS and injected intraperitoneally into 3-d-old BDC2.5/
NOD.Foxp3sf recipients. To examine cytokine expression, subsets of BDC2.5
clonotypehi were sorted from PLN of 15-d-old mice. RNA was extracted
from these cells with TRIzol (Invitrogen). Ex vivo analysis of IL2 and IFN 
production were done using quantitative RT-PCR with sorted PLN
BDC2.5-clonotypehiCD25 /lo effector cells, which included both CD69 
CD25lo and CD69  cells, as described previously (8). 
 For the experiment of cotransferring T eff and T reg cells, splenocytes
from BDC2.5/NOD.Thy1.1 mice were labeled with CFSE and then de-
pleted of CD25  and CD69  cells with MACS-beads (Miltenyi Biotec).
CD4 CD25  or CD4 CD25  were sorted as above from the spleen of
BDC2.5/NOD mice. CFSE-labeled effectors (0.6- to 1.2   106 cells) alone,
or mixture of CFSE-labeled effectors with CD25  T reg cells or CD25 
control cells at 10:1 or 3:1 ratio, were injected into normal 5-wk-old NOD
mice. Dilution of CFSE in Thy1.1  cells was analyzed by flow cytometry. 
Gene expression profiling. Pancreata, PLNs, or MLNs were isolated
from 3–4 wk-old BDC2.5/NOD mice (n   10-20 mice per RNA sample).
Cells were stained with CD4-PECy7 (GK1.5), B220-PE–Texas red (RA3-
6B2), 7AAD live cell dye, CD25-APC (PC61), and CD69-FITC (H1.2F3;
BD Biosciences). Live B220 CD4  cells were sorted to separate the
CD4 CD25 CD69  population (T reg) and the combined population of
all other CD4  cells (CD4 CD25 CD69  and CD4 CD25lo/ CD69 
cells), using a MoFlo flow cytometer and Summit® software. Sorted cells
were collected into media with 5% fetal bovine serum, and assessed for pu-
rity. If necessary, cells were resorted to achieve  98% purity. Cells (typi-
cally 104–105 cells per experiment) were lysed in TRIzol, and total RNA
prepared according to manufacturer’s instructions (Invitrogen). RNA was
amplified twice using the MessageAmp RNA kit (Ambion), except the bio-
tinylation step was performed using the BioArray HighYield RNA Tran-
script Labeling Kit (T7) (Enzo Life Sciences). 5–15  g of an RNA probe
was hybridized to murine genome U74Av2 array GeneChips as per manu-
facturer’s instructions (Affymetrix) by the Joslin Genomics Core. The raw
data were processed with the RMA algorithm for probe-level normalization
(8) (S  ArrayAnalyzer, Insightful, modified by R. Park, D.M. and C.B.) and
composite expression values were calculated for each of the genes on the
chip (averaging after outlier elimination, “Distill” software). Gene-wise
p-values were calculated with Welch’s modified t test. A randomized dataset
was generated using inter-replicate CVs to estimate false-discovery rates.
Prior data from earlier pancreas infiltrate samples (8) (GEO database acces-
sion no. GSE1419), was pooled and distilled together with newly generated
pancreas samples prepared in parallel with the PLN and MLN samples gen-
erated for this study (GSE1419). 
Online supplemental material. Specific genes identified by microarray
analysis of T reg and T eff cells are presented in Table S1. Online sup-
plemental material is available at http://www.jem.org/cgi/content/full/
jem.20051409/DC1. 
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